… advanced non-small-cell lung cancer (NSCLC) allowed precise … for the entire tumor genome,
circulating tumor DNA (ctDNA) … of tumor burden, acquired resistance, tumor heterogeneity …

… The results of this study provide straightforward evidence of an increased amount of tumor
circulating DNA in the plasma of lung cancer patients. To evaluate the accuracy of the DNA …

… In lung cancer liquid biopsies, blood samples are mainly used as a sample source for
analyzing circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA), in addition to other …

… of circulating-tumor DNA (ctDNA) in cases diagnosed with small-cell lung cancer (SCLC). …
patients including those with early-stage tumors. Importantly, we also provide evidence that …

… Circulating tumor DNA (ctDNA) are short DNA fragments providing a comprehensive view
of the tumor as were shed by tumor cells from multiple tumor regions (1). Application of ctDNA …

… of 430 cancer-related genes in … tumor DNA sequencing is promising to delineate genomic
landscape, subclonal architecture and investigate genomic evolution of small-cell lung cancer …

… as non–small-cell lung cancer (NSCLC), these assays usually measure circulating tumor
DNA (ctDNA), which is composed of tumor-derived mutations in plasma cell-free DNA (cfDNA). …

… of lung cancer treatment by … tumor DNA (ctDNA) obtained from peripheral blood could be
used to predict immunotherapy response in patients with metastatic non–small cell lung cancer. …

… non-small cell lung cancers as their tumors may harbor somatic … advanced non-small cell
lung cancer to targeted therapy and in … cell lung cancer in the real-world clinical practice setting. …

… apply cancer personalized profiling by deep sequencing (CAPP-seq) circulating tumor
DNA … treated with curative intent for stage I–III lung cancer and 54 healthy adults. In 94% of …